# Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

> **NCT06712888** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 466 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma (NPC)

## Interventions

- **DRUG:** TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy
- **DRUG:** GP plus placebo induction therapy

## Key facts

- **NCT ID:** NCT06712888
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2030-01-01
- **Final completion:** 2032-01-01
- **Target enrollment:** 466 (ESTIMATED)
- **Last updated:** 2025-03-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06712888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06712888, "Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06712888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*